HurwitzH., FehrehnbacherL., NovotnyW.: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer.N Engl J Med, 350: 2335–2342, 2004.
2.
MinagawaN., NakayamaY., HirataK.: Correlation of plasma level and immunohistoche-mical expression of VEGF in patients with advanced colorectal cancer.Anticancer Res, 22: 2957–2963, 2002.
3.
WillettC.G., BoucherY., Di TomasoE.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.Nat Med, 10: 146–147, 2004.
4.
LeeJ.C., ChowN.H., WangS.T.: Prognostic value of VEGF expression in colorectal cancer patients.Eur J Cancer, 36: 748–753, 2000.
5.
KabbinavarF., HurwitzH., FehrenbacherL.: Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with 5FU/LV alone in patients with metastatic colorectal cancer.J Clin Oncol, 21: 60–65, 2003.
6.
KabbinavarF.F., SchulzJ., McCleodM.: Bevacizumab to prolong progression-free survival in first-line colorectal cancer in subjects who are not suitable candidates for first-line CPT-11.J Clin Oncol, 22(suppl): abstr 3516, 2004.
7.
MassR.D., FyfeG., HambletonJ.: Bevacizumab in combination with 5-FU/LV improves survival in patients with metastatic colorectal cancer: a combined analysis.J Clin Oncol;22(suppl): abstr 3616, 2004.
8.
HochsterH.S., WellesL., HartL.: Safety and efficacy of bevacizumab when added to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer: TREE 1 and 2 studies.Proc ASCO, abstr 3515, 2005.
9.
GiantonioB.J., CatalanoP.J., MeropolN.J.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from Eastern Cooperative Oncology group study E3200.Proc ASCO, abst 2, 2005.
10.
SaltzL., LenzH.J., HochsterH.: Randomized phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer.J Clin Oncol, 23(suppl): abstr 3508, 2005.
11.
CunninghamD., HumbletY., SienaS.: Cetu-ximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N Engl J Med, 351: 337–345, 2004.
12.
YangJ.C., HaworthL., SherryR.M.: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer.N Engl J Med, 349: 427–434, 2003.
13.
SpigelD.R., HainsworthJ.D., SosmanJ.A.: Bevacizumab and erlotinib in the treatment of patients with metastatic renal cell carcinoma. (RCC): update of a phase II multicenter trial.Proc ASCO, abst 4540, 2005.
14.
SandlerA.B., GrayR., BrahmerJ.: A randomized phase III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non squamous NSCLC: an ECOG trial E4599.Proc ASCO, abstr LBA4, 2005.
15.
KindlerH.L., FribergG., StadlerW.M.: Bevacizumab plus gemcitabine in patients with advanced pancreatic cancer: updated results of a multicenter phase II trial.J Clin Oncol, 22(suppl): abstr 4009, 2004.
16.
CobleighM.A., LangmuirV.K., SledgeG.W.: A phase I/II dose escalation trial of bevacizumab in previously treated metastatic breast cancer.Semin Oncol, 30: 117–124, 2003.
17.
MillerK.D., RugoH.S., CobleighM.A.: Phase III trial of capecitabine plus bevacizumab versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane.Breast Cancer Res Treat, 79: abstr 36, 2002.
18.
MillerK.D., WangM., GralowJ.: A randomized phase III trial of paclitaxel versus paclitaxel and bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer.Proc ASCO2005, oral presentation.
19.
Meta-analysis of randomized trials testing the biochemical modulation of 5FU by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project.J Clin Oncol, 12: 960–969, 1994.
20.
ArkenauH.T., SchmollH., KubickaS.: Infusional FUFOX versus CAPOX as first line treatment of metastatic colorectal cancer: results of the safety and efficacy analysis.Proc ASCO, A3507, 2005.
21.
SeymourM.T. for the UK NCRI Colorectal Clinical Studies Group: Fluorouracil, oxaliplatin and CPT11 use and sequencing (MRC FOCUS): a 2135 patient randomized trial in advanced colorectal cancer.Proc ASCO, A3518, 2005.
22.
GoldbergR.M., SargentD.J., MortonR.F.: A randomised controlled trial of 5FU plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J Clin Oncol, 22: 23–30, 2004.
23.
TournigandC., AndrèT., AchilleE.: FOLFI-RI followed by FOLFOX 6 or the riverse sequenze in advanced colorectal cancer: a randomized GERCOR study.J Clin Oncol, 22: 229–237, 2004.
24.
International Multicentric Pooled Analysis of Colon Cancer Trials Investigators - IMPACT: efficacy of adjuvant 5FU and folinic acid in colon cancer.Lancet, 345: 939–944, 1995.
25.
AndrèT., BoniC., Mounedji-BoudiafL.: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer.N Engl J Med, 350: 2343–2351, 2004.
26.
CassidyJ., ScheithauerW., McKendrickG.: Capecitabine (X) vs bolus 5FU/LV as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial.Proc ASCO, abstr 3509, 2004.
